Company also establishes Medical Advisory Board
The company also announced the formation of a Medical Advisory Board, which includes: Theodore J. Dubinsky, M.D., University of Washington Medicine; Sadik C. Esener, Ph.D., Cancer Early Detection and Response Institute; Santosh Kesari, M.D., Ph.D., John Wayne Cancer Institute; Aizik L. Wolf, M.D., Radiosurgery Neurosurgeon, Private Practice; and, Wolf Wrasidlo, Ph.D., UC San Diego Moores Cancer Center.
Dr. Makale is Assistant Adjunct Professor of Radiation Medicine and Applied Science at UC San Diego Moores Cancer Center. Dr. Makale is a co-founder of Global Cancer Technology; a co-founder of MCW Pharmaceuticals; and an adviser to RusNano, Chinese Pharma, Trogenex, and Imagion.
“GCT will benefit greatly from not only Dr. Makale’s special expertise but also his demonstrated translational business acumen,” said John Clark, CEO. “Indeed, Milan‘s outstanding reputation has enabled GCT to create a stellar Medical Advisory Board, which will fortify our efforts to translate GCT’s innovative and patented technology and realize the potential to significantly improve anticancer treatment outcomes.”
GCT is initially focused on developing its advanced drug delivery platform technology, Scintillating NanoCrystals (SNCs): nanosized injectable particles linked to cancer drug molecules in order to transport to, and then selectively decimate, deep-seated tumors via extremely low-dose external radiation. The SNC platform is exclusively licensed to the company from the University of California San Diego (UCSD). Inactive cancer drug molecules are attached to GCT’s nanosized scintillators made of nanocrystals that are activated at the tumor site by a very low dose of external radiation, designed to release the drug molecules’ full potency without harming surrounding tissue.
San Diego-based Global Cancer Technology is an emerging medical technology company with a robust pipeline focused on fighting cancer.
CAUTION: The company’s Scintillating NanoCrystals (SNCs) not approved for human use at this time.
Ronald Trahan, APR, Ronald Trahan Associates, +1-508-816-6730, [email protected]